Sera Prognostics (SERA) to Announce Quarterly Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA) is expected to be issuing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $0.0710 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, May 6th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.07 million. Sera Prognostics had a negative return on equity of 41.02% and a negative net margin of 56,385.97%. On average, analysts expect Sera Prognostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sera Prognostics Stock Down 1.0%

Shares of NASDAQ:SERA opened at $2.03 on Wednesday. The stock has a market cap of $79.49 million, a PE ratio of -3.12 and a beta of 0.97. The company’s fifty day moving average is $2.01 and its 200 day moving average is $2.24. Sera Prognostics has a 52 week low of $1.56 and a 52 week high of $3.95.

Insider Activity at Sera Prognostics

In related news, CEO Zhenya Lindgardt sold 20,755 shares of Sera Prognostics stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $2.08, for a total value of $43,170.40. Following the transaction, the chief executive officer directly owned 871,999 shares of the company’s stock, valued at $1,813,757.92. The trade was a 2.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 27,755 shares of company stock valued at $57,840 over the last quarter. 11.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Sera Prognostics

A number of large investors have recently added to or reduced their stakes in SERA. Squarepoint Ops LLC boosted its holdings in shares of Sera Prognostics by 8.9% during the third quarter. Squarepoint Ops LLC now owns 93,063 shares of the company’s stock worth $285,000 after purchasing an additional 7,643 shares during the period. Citadel Advisors LLC lifted its stake in Sera Prognostics by 1.9% in the third quarter. Citadel Advisors LLC now owns 653,746 shares of the company’s stock worth $2,000,000 after acquiring an additional 12,439 shares during the period. Lido Advisors LLC purchased a new position in Sera Prognostics during the 3rd quarter valued at $68,000. Cetera Investment Advisers bought a new position in Sera Prognostics in the 4th quarter worth $74,000. Finally, Barclays PLC raised its position in shares of Sera Prognostics by 267.4% in the 4th quarter. Barclays PLC now owns 36,722 shares of the company’s stock worth $108,000 after acquiring an additional 26,726 shares in the last quarter. Institutional investors own 54.64% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Craig Hallum started coverage on Sera Prognostics in a report on Thursday, June 4th. They issued a “buy” rating and a $6.00 price objective on the stock. Weiss Ratings upgraded Sera Prognostics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $5.50.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.